Peptides - Compound guides
TB-500 and Thymosin Beta-4
TB-500 is a synthetic fragment of the natural protein Thymosin Beta-4, studied mainly in animals and cell models, with no established human clinical evidence.
To understand TB-500 you first have to separate two things that are routinely conflated online. Thymosin Beta-4, often abbreviated TB4, is a real protein found naturally in human cells - a chain of 43 amino acids that is one of the most abundant proteins inside many cell types and is involved in the organisation of the cellular skeleton. TB-500 is not that protein. TB-500 is a shorter synthetic fragment, based on a small active region of the Thymosin Beta-4 sequence, produced in a laboratory because a short fragment is far cheaper and easier to synthesise than the full protein.
This distinction matters when reading claims. Research published on the full Thymosin Beta-4 protein is frequently cited as though it were research on TB-500, and the two are not interchangeable. A fragment may behave differently from the parent molecule in stability, in distribution and in what it binds to. When you see a study referenced in support of TB-500, the first question worth asking is which of the two molecules was actually tested.
How it is thought to work
The proposed mechanism centres on actin, a protein that forms part of the internal scaffolding of cells. Thymosin Beta-4 binds actin monomers and influences how the cellular skeleton is assembled and disassembled. Because cell migration - cells physically moving into an area of damage - depends on rearranging that skeleton, the hypothesis is that a compound influencing actin dynamics could influence how cells move and organise during tissue repair. The specific short sequence on which TB-500 is based is the region thought to be responsible for actin binding.
Secondary proposed mechanisms in the preclinical literature include effects on the formation of new blood vessels and on inflammatory signalling in animal tissue. As with any compound at this stage, these should be read as proposed and partially characterised mechanisms observed in non-human systems, not as demonstrated actions in the human body. A mechanism that makes sense on paper is a reason to run a trial, not a substitute for one.
What the research actually shows
The evidence for TB-500 and Thymosin Beta-4 sits on the lower rungs of the evidence ladder. There is a genuine body of cell culture work on Thymosin Beta-4, going back decades, characterising its actin-binding behaviour - that basic biology is reasonably well established. Above that there is a set of animal studies, in rodents and in some larger animal models, reporting effects in models of cardiac injury, corneal damage, skin wounds and tendon injury. Some of this animal work is of decent quality and comes from more than one group.
Where the evidence stops abruptly is at the human rung. The full Thymosin Beta-4 protein has been through some early-stage human trials, notably in ophthalmology and dermatology contexts, which is more than most compounds in this category can claim - but those trials were exploratory, and did not deliver an approved product. For TB-500 specifically, the shorter synthetic fragment that is actually sold and discussed online, human evidence is essentially absent. There are no published randomised controlled trials in humans establishing that it produces any clinical effect. The confident claims circulating in sports and recovery communities about accelerated healing are extrapolations from rodent studies, and rodent studies do not establish human outcomes.
It is also worth noting that a great deal of the enthusiasm for TB-500 originated in veterinary and equine contexts, where it circulated in racing before drawing regulatory attention. That history explains some of the folklore around the compound, but folklore is not data. There is no long-term human safety dataset for TB-500, and none for the injected use of Thymosin Beta-4 outside a small number of controlled research settings.
Where the evidence stops
- TB-500 and Thymosin Beta-4 are different molecules, and evidence for one is routinely and incorrectly cited for the other.
- No published randomised controlled human trials show a clinical effect from TB-500.
- Early human work on the full Thymosin Beta-4 protein was exploratory and did not lead to an approved medicine.
- Human pharmacokinetics for the synthetic fragment are not established.
- No long-term human safety data exists, and the effects of prolonged exposure are unknown.
- As with any compound influencing cell migration and blood vessel formation, the interaction with abnormal tissue growth is an unresolved theoretical question.
- Research-chemical material carries no pharmaceutical quality assurance, so purity and identity are unverified variables.
Legal and regulatory status
Neither TB-500 nor Thymosin Beta-4 is an approved medicine in the United Kingdom for general human use. There is no MHRA marketing authorisation, and material sold under these names is typically supplied as a research chemical labelled not for human consumption. Products sold in that category are outside the medicines regulatory system entirely: they are not made under pharmaceutical manufacturing standards, not independently verified for identity, purity or sterility, and not subject to the batch controls that a licensed medicine must meet.
In sport, the position is explicit. Thymosin Beta-4 is named on the World Anti-Doping Agency prohibited list under the section covering growth factors and peptide signalling agents, and it is prohibited at all times, both in and out of competition. TB-500, as a fragment of that sequence, falls under the same prohibition. Anti-doping cases involving these compounds have been brought in both human and equine sport. Anyone subject to anti-doping testing should treat the compound as clearly prohibited rather than as a grey area.
This lesson is educational content only and is not medical advice. TB-500 is not an approved medicine in the UK or elsewhere for any human use, and human clinical evidence for it is essentially absent. Any decision relating to your health belongs with a qualified healthcare professional who knows your medical history.
Recovery and repair peptides
Start with the overview: Recovery and repair peptides, explained
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
